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Abstract
Toll-like receptors (TLR) and the downstream adaptor protein MyD88 are considered crucial
for protective immunity during bacterial infections. Streptococcus (S.) pneumoniae is a
human respiratory pathogen and a large majority of clinical pneumococcal isolates ex-
presses an external polysaccharide capsule. We here sought to determine the role of pneu-
mococcal capsule in MyD88-mediated antibacterial defense during S. pneumonia
pneumonia. Wild type (WT) andMyd88-/-mice were inoculated intranasally with serotype
2 S. pneumoniae D39 or with an isogenic capsule locus deletion mutant (D39Δcps), and
analysed for bacterial outgrowth and inflammatory responses in the lung. As compared to
WTmice,Myd88-/-mice infected with D39 demonstrated a modestly impaired bacterial
clearance accompanied by decreased inflammatory responses in the lung. Strikingly, while
WTmice rapidly cleared D39Δcps,Myd88-/-mice showed 105-fold higher bacterial burdens
in their lungs and dissemination to blood 24 hours after infection. These data suggest that
the pneumococcal capsule impairs recognition of TLR ligands expressed by S. pneumoniae
and thereby partially impedes MyD88-mediated antibacterial defense.
Introduction
Streptococcus (S.) pneumoniae frequently resides in the upper respiratory tract of humans and
other related mammalian species [1]. At least 93 capsular serotypes of pneumococci exist in
humans and once colonized by a new serotype, the pneumococcus can persist for weeks or
even months without causing disease. In a subset of subjects, colonization leads to invasive
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infection, making S. pneumoniae the most common causative microorganism in community-
acquired pneumonia (CAP) [2,3]. In the United States alone, the pneumococcus is responsible
for more than half a million CAP cases each year, with a fatality rate of 5–7% [4]. Knowledge of
host defense mechanisms that influence the outcome of pneumococcal pneumonia may aid in
developing novel therapeutic strategies in an era of growing resistance of the pneumococcus
against currently available antimicrobial agents [2,3].
Toll-like receptors (TLRs) play a central role in the initiation of cellular innate immune re-
sponses by virtue of their capacity to detect pathogens at either the cell surface or in lysosomes/
endosomes [5,6]. Ten TLRs have been identified in humans and 12 in mice. Different TLRs
recognize different conserved motifs expressed by pathogens called “pathogen associated mo-
lecular patterns”. TLRs can sense several of these patterns within S. pneumoniae and thereby
contribute to the induction of an effective innate immune response. TLR2 has been implicated
as the principal TLR in the recognition of S. pneumoniae [7–9], at least in part through an in-
teraction with lipoteichoic acid, a constituent of the pneumococcal cell wall [10–12]. Nonethe-
less, TLR2 does not play a major role in containment of the infection during pneumococcal
pneumonia [8,13]. TLR4 contributes to host defense during S. pneumoniae pneumonia
through its capacity to recognize pneumolysin [14,15]. The interaction between pneumolysin
and TLR4 has been found to limit the growth of pneumococci in the nasopharynx in a model
of colonization [14,15] whereas TLR4 may also contribute to antibacterial defense during
pneumococcal infection of the lower airways [16]. Finally, TLR9, which recognizes bacterial
DNA, was found to be required to control bacterial growth and dissemination after induction
of pneumococcal pneumonia [17]. All TLRs, except TLR3, rely on myeloid differentiation pri-
mary-response protein 88 (MyD88) for signaling. In accordance with a role for TLR signaling
in host defense against pneumococcal pneumonia, MyD88 deficient (Myd88-/-) mice were re-
ported to show a profoundly enhanced growth of pneumococci and a strongly reduced survival
after intranasal infection with serotype 4 or 19F S. pneumoniae strains [18].
At least 93 different serotypes of S. pneumoniae have been identified based on antigenic dif-
ferences in their capsular polysaccharides. The capsule of S.pneumoniae is a major virulence
factor, as illustrated by the fact that virtually all clinical isolates contain a capsule and that non-
encapsulated pneumococcal strains are markedly less virulent in animals [19]. The pneumo-
coccal capsule provides protection against phagocytosis [19], complement-mediated immunity
[20] and opsonophagocytic killing [21]. Furthermore, the capsule markedly reduces capture of
pneumococci by neutrophil extracellular traps [22]. Moreover, the capsule also prevents en-
trapment of S. pneumoniae in airway mucus and as a consequence limits mucus-mediated
clearance [23]. The capsule potentially also interferes with innate immune responses by mask-
ing several TLR ligands associated with the pneumococcal cell wall, including lipoteichoic acid
and lipopeptides [3,19]. Therefore, we here hypothesized that the pneumococcal capsule may
impede TLR-mediated protective immunity during infection with S. pneumoniae. Hence, in
the present study we investigated the host response during pneumonia caused by the serotype
2 strain D39 and an isogenic capsule locus (cps) deletion mutant of D39 (D39Δcps) [24] in both
wild type (WT) andMyd88-/- mice. Our findings reveal that the polysaccharide capsule partial-
ly protects pneumococci against MyD88-mediated immunity during pneumonia in mice.
Materials and Methods
Ethics statement
Experiments were carried out in accordance with the Dutch Experiment on Animals Act and
approved by the Animal Care and Use Committee of the University of Amsterdam (Permit
number DIX 100121).
Pneumococcal Capsule in MyD88-Mediated Immunity
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Mice
C57BL/6 WTmice were purchased from Harlan Sprague Dawley Inc. (Horst, The Nether-
lands) andMyd88-/- mice [25], backcrossed 7 times to a C57BL/6 genetic background, were
generously provided by Dr. Shizuo Akira (Osaka University, Japan). All mice were bred and
housed in specific pathogen-free rooms within the animal facility of the Academic Medical
Center (Amsterdam, The Netherlands). Age (9–11 week old) and gender matched mice were
used in all experiments.
Bacteria
The S. pneumoniae strains used in this study were D39 and D39Δcps, the isogenic capsule locus
(cps) deletion mutant of WT D39 [24]. Both D39 and D39Δcps were grown for 3–6 hours to
mid-logarithmic phase at 37°C using Todd-Hewitt broth (Difco, Detroit, MI), supplemented
with yeast extract (0.5%). Bacteria were harvested by centrifugation at 4000 rpm, and washed
twice in sterile isotonic saline.
Experimental design
Pneumonia was induced by intranasal administration of bacteria (total volume 50 μl) under
light anaesthesia by inhalation of isoflurane (Abbott, Kent, UK) as described previously
[8,12,26]. Mice were killed 6 or 48 hours after infection with D39 pneumococci (5 x 106 colony
forming units (CFU)), and 6 or 24 hours after infection with D39Δcps bacteria (108 CFU)(N =
6–8 per group at each time point). The infectious dose of D39Δcps was chosen based on the
fact that lower doses are rapidly cleared from the airways by normal WTmice [27]. Lung bacte-
rial loads were determined as described earlier [8,12,26]. Briefly, mice were sacrificed and
blood and lungs were collected. Lungs were homogenized at 4°C in 5 volumes of sterile isotonic
saline with a tissue homogenizer (Biospect Products, Bartlesville, OK). Serial 10-fold dilutions
in sterile isotonic saline were made from these homogenates (and blood), and 50 μl volumes
were plated onto sheep-blood agar plates and incubated overnight at 37°C and 5% CO2.
Histology
Lungs for histology were fixed in 10% formalin and embedded in paraffin. Four μm sections
were stained with hematoxylin and eosin (HE) and analyzed by a pathologist who was blinded
for groups. To score lung inflammation and damage, the entire lung surface was analyzed with
respect to the following parameters: bronchitis, edema, interstitial inflammation, intra-alveolar
inflammation, pleuritis and endothelialitis. Each parameter was graded on a scale of 0 to 4 with
0 as ‘absent’ and 4 as ‘severe’. The total “lung inflammation score” was expressed as the sum of
the scores for each parameter, the maximum being 24. Sections were stained with FITC-labeled
anti-mouse Ly6-C/G mAb (BD Biosciences, San Jose, CA) to determine granulocyte infiltration
in the lung, as described before [27]. Ly6-C/G expression in the lung was quantified by digital
image analysis and the amount of Ly6-C/G positivity was expressed as a percentage of the total
surface area, as described [27].
Assays
Lung homogenates were prepared as described [8,12,26]. Myeloperoxidase (MPO) was mea-
sured by ELISA (HyCult, Uden, The Netherlands). Tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, IL-6, macrophage inflammatory protein (MIP)-2 and cytokine-induced neutrophil
chemoattractant (KC) were measured by ELISA (R & D Systems, Abingdon, UK).
Pneumococcal Capsule in MyD88-Mediated Immunity
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Statistical analysis
Statistical analysis was performed with GraphPad Prism version 4.00 for Windows (GraphPad
Software, San Diego, CA). All data are given as means ± SEM. Differences between groups
were analyzed using Mann-Whitney U test. P< 0.05 was considered to present a statistically
significant difference.
Results
MyD88 especially limits bacterial growth and dissemination during
pneumonia caused by non-encapsulated S. pneumoniae
To determine the impact of the pneumococcal capsule on MyD88 mediated antibacterial de-
fense, we infected WT andMyd88-/- mice with either WT encapsulated D39 S. pneumoniae or
with isogenic non-encapsulated D39Δcps pneumococci via the airways. After instillation of
D39 we euthanized mice 6 or 48 hours after infection for measurements of bacterial loads in
lungs and blood, seeking to obtain insight into the role of MyD88 in the early and late host re-
sponse (Fig. 1A). At both time points,Myd88-/- mice had higher bacterial loads in their lungs
than WTmice (P<0.05), although the differences between mouse strains were relatively
modest. MyD88 deficiency was not associated with enhanced dissemination of D39 to the
circulation (Fig. 1A). Since we previously found that WT mice cleared high D39Δcps doses
within 24 hours [27],Myd88-/- and WTmice were sacrificed 6 or 24 hours after infection with
D39Δcps, again seeking to obtain information about the early and late host response (Fig. 1B).
Analysis of bacterial outgrowth in the lung showed thatMyd88-/- mice had a strongly dimin-
ished capacity to clear D39Δcps: whereas WT mice demonstrated a>105-fold reduction in pul-
monary bacterial loads between 6 and 24 hours after infection, the reduction inMyd88-/- mice
was only ~102-fold in this time frame. At both time points the lungs of MyD88-/- mice con-
tained much higher burdens of D39Δcps as compared to the lungs of WT mice (P<0.005); at
24 hours after infection the average difference was as high as 105-fold. Importantly, dissemina-
tion of D39Δcps to the circulation was only found inMyd88-/- mice, not in WT mice, 24 hours
Fig 1. Enhanced susceptibility of Myd88-/- mice for D39 or D39Δcps. (A) Bacterial loads in lung homogenates of wild type mice (WT, black bars) and
Myd88-/- mice (MyD88 KO, white bars) at 6 and 48 hours after infection with 5x106 CFU S. pneumoniae D39, and (B), 6 and 24 hours after infection with
1x108 CFU D39Δcps. BC+ indicates the number of positive blood cultures. Data are mean ± SEM. (N = 6–8 mice per group at each time point). *P<0.05,
**P<0.005, ***P<0.0005 vs WTmice.
doi:10.1371/journal.pone.0118181.g001
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after infection (P<0.005). These results indicate that MyD88 has a stronger impact on antibac-
terial defense after infection with the non-encapsulated D39Δcps strain.
MyD88 mediates the early inflammatory response in the lung during
pneumonia caused by capsulated and non-encapsulated S.
pneumoniae
The induction of a brisk inflammatory response in the lungs is of great importance for contain-
ment of the infection during pneumococcal pneumonia [3,28]. To obtain insight into the
mechanism underlying the role of MyD88 in limiting bacterial growth after infection with D39
and D39Δcps pneumococci, we prepared lung tissue slides from mice at different time points
after infection with either bacterial strain and analysed specific histological features characteris-
tic for bacterial pneumonia. Lung pathology developed quickly in WT mice after infection with
D39 (Fig. 2A and C), and was characterised by pleuritis, interstitial inflammation, endotheliali-
tis, bronchitis and edema. In contrast,Myd88-/- mice demonstrated strongly reduced lung in-
flammation early after infection with D39 (P<0.01 vs WT mice), caused by reduced pleuritis,
interstitial inflammation, bronchitis, endothelialtis and edema (Fig. 2B-C). At 48 hours after
inoculation, the extent of lung pathology had decreased in WTmice and increased inMyd88-/-
mice; the difference between mouse strains was not observed anymore (Fig. 2D-F). In spite of
the strongly reduced virulence of D39Δcps, this pneumococcal strain elicited a marked inflam-
matory response in the lungs of WT mice. The extent of lung inflammation was much lower in
Myd88-/- mice at 6 hours (P<0.005 versus WT mice), caused by reduced interstitial inflamma-
tion, endothelilitis, bronchitis and edema (Fig. 2G-I). At 24 hours after infection with D39Δcps,
there was no difference in lung pathology between WT andMyd88-/- mice (Fig. 2J-L).
In accordance with these histological data, D39 triggered an early and transient neutrophil
influx into the lungs of WT mice, as reflected by a marked increase in the number of Ly6+ cells
in tissue slides and elevated concentrations of MPO in whole lung homogenates at 6 hours
post infection, which was strongly reduced inMyd88-/- mice (Fig. 3A-D, both P<0.0005). At
48 hours after infection with D39, neutrophil counts in lungs had declined strongly in WT
mice and were not different from those inMyd88-/- mice. Similarly, Ly6-C/G staining and
MPOmeasurements revealed that D39Δcps induced a rapid and transient influx of neutrophils
into lung tissue of WT mice at 6 after inoculation, which was not observed inMyd88-/- mice
(Fig. 3E-H, both P<0.0005). At 24 hours post D39Δcps inoculation, neutrophil infiltration in
the lung had strongly decreased in WTmice; at this time pointMyd88-/- mice still had fewer
Ly6+ cells in lung tissue when compared with WTmice (P<0.05).
Role of MyD88 in the cytokine and chemokine response in the lung
during pneumonia caused by capsulated and nonencapsulated S.
pneumoniae
Local production of cytokines and chemokines plays an eminent role in the orchestration of
the inflammatory response in the lungs during pneumococcal pneumonia [3]. We therefore
considered it of interest to examine the impact of MyD88 deficiency on the concentrations of
proinflammatory cytokines (TNF-α, IL-1β, IL-6) and CXC chemokines (KC, MIP-2) after in-
fection with D39 or D39Δcps (Figs. 4 and 5). Inoculation with D39 induced a brisk cytokine
and chemokine response at 6 hours with much lower levels at 48 hours. Importantly, relative to
WT mice,Myd88-/- mice showed a markedly attenuated cytokine and chemokine response at
6 hours after infection with D39 (P<0.005 in all cases; Figs. 4 and 5). Strikingly, the capacity of
D39Δcps to induce the production of most cytokines in the lung was rather low as compared to
D39 (Fig. 4), with pulmonary TNF-α and IL-6 levels at 6 hours after inoculation of D39Δcps in
Pneumococcal Capsule in MyD88-Mediated Immunity
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WTmice significantly reduced as compared to D39 (P<0.0005 in both cases). In contrast, IL-
1β concentrations were strongly elevated in WT mice, but not inMyd88-/- mice 6 hours after
inoculation of D39Δcps (P<0.0005; Fig. 4D). Besides IL-1β, D39Δcps also induced an early and
transient increase of MIP-2 levels in the lung of WT mice, but not inMyd88-/- mice (Fig. 5D).
The induction of KC in the lung of WT mice by D39Δcps was markedly reduced as compared
to D39 (P<0.05; Fig. 5).
Fig 2. Lung pathology in WT andMyd88-/- mice during infection with capsulated and unencapsulated D39. Representative lung sections obtained 6 or
48 h after induction of pneumococcal pneumonia with D39 in WT (A and D) and Myd88-/- mice (B and E) and 6 or 24 h after inoculation with D39Δcps in WT
mice (G and J) and MyD88-/- mice (H and K). Haematoxylin and eosin stainings show different levels of inflammation. Original magnification 20x. Findings
were quantified by histology scoring, as described in methods section for wild type (WT, black bars) and Myd88-/- mice (MyD88 KO, white bars). Data are
mean ± SEM (N = 5–8 mice per group at each time point). **P<0.005 vsWTmice.
doi:10.1371/journal.pone.0118181.g002
Pneumococcal Capsule in MyD88-Mediated Immunity
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Discussion
The polysaccharide capsule is a major virulence factor of S.pneumoniae rendering bacteria re-
sistant to the lethal effects of complement, shielding bacteria from opsonophagocytosis and
killing, inhibiting capture by neutrophil extracellular traps and limiting mucus-mediated clear-
ance [19–23]. Studies with capsular switch mutants revealed that the capsule rather than the
genetic background influences resistance of S. pneumoniae to host immune responses and viru-
lence in mice [20,21,29]. Since TLR ligands are masked by capsular polysaccharides in certain
bacteria [30,31], we here studied the role of the pneumococcal capsule in MyD88-mediated an-
tibacterial defense against S. pneumoniae using the serotype 2 strain D39 and D39Δcps. While
the present finding of enhanced bacterial growth of D39 inMyd88-/- mice is in accordance
with earlier results after infection with serotype 4 or 19F S. pneumoniae [18], we demonstrate
that MyD88 plays a more important role in limiting pneumococcal growth after infection
with D39Δcps. WhereasMyd88-/- mice infected with D39 displayed a modestly impaired bacte-
rial clearance, these knock-out mice showed 105-fold higher bacterial burdens in their lungs
24 hours after infection with D39Δcps as compared to WT mice. These data suggest that part of
the virulence of encapsulated pneumococci relies on the capacity of the capsule to impair rec-
ognition of TLR ligands expressed by S. pneumoniae.
In line with previous studies [27,32,33], loss of the capsule greatly attenuated the virulence
of D39 in WTmice. Analysis of the cytokine and chemokine responses in the lung showed that
D39, but not D39Δcps pneumococci despite higher bacterial numbers, triggered the production
of TNF-α, IL-6 and KC in the lung 6 hours after infection. These findings indicate that the cap-
sule is a major factor in the early induction of cytokines at the primary site of infection with S.
pneumoniae. Although pneumococcal polysaccharides do not directly trigger TLR signaling,
the early cytokine response evoked by D39 was strongly attenuated inMyd88-/- mice. These re-
sults suggest that pneumococcal polysaccharides or components associated with polysaccha-
rides on the outmost surface of the bacterium enhance TLR dependent cytokine release elicited
Fig 3. Reduced neutrophil infiltration in the lung in Myd88 -/- mice during infection with D39 or D39Δcps. Representative Ly6-C/G stainings of lung
sections obtained 6 h after induction of pneumococcal pneumonia with D39 in WT and Myd88-/- mice (A and B) and with D39Δcps in WTmice and Myd88-/-
mice (E and F). Original magnification 20x. Percentage lung area with Ly6-C/G-positive neutrophils was quantified by digital image analysis as described in
methods section for wild type (WT, black bars) and Myd88-/- mice (MyD88 KO, white bars)(C and G). Levels of MPO in lung homogenates of wild type (WT,
black bars) and Myd88-/- mice (MyD88 KO, white bars) inoculated with D39 at 6 and 48 hours after challenge, or inoculated with D39Δcps (D and H) at 6 and
24 hours after challenge were determined by ELISA. Data are mean ± SEM (N = 5–8 mice per group at each time point). *P<0.05, ***P<0.0005 vs
WTmice.
doi:10.1371/journal.pone.0118181.g003
Pneumococcal Capsule in MyD88-Mediated Immunity
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by pneumococcal TLR ligands such as lipoteichoic acid, pneumolysin and DNA. A possible
mechanism may be that capsular polysaccharides facilitate binding of pneumococci to cells
(e.g. via C-type lectin receptors) and thereby augment cytokine production. Further studies
are required to determine the role of the pneumococcal capsule in induction of distinct
Fig 4. Reduced cytokine production in the lung of Myd88-/- mice during infection with D39 or D39Δcps. Lung levels of TNF-α (A and B), IL-1β (C and
D) and IL-6 (E and F) of wild type (WT, black bars) and Myd88-/- mice (MyD88 KO, white bars) at 6 and 48 hours after inoculation with D39 (A/C/E) or at 6 or
24 hours post inoculation of D39Δcps (B/D/F). Data are mean ± SEM (N = 6–8 mice per group at each time point). *P<0.05, **P<0.005, ***P<0.0005 vs
WTmice.
doi:10.1371/journal.pone.0118181.g004
Pneumococcal Capsule in MyD88-Mediated Immunity
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inflammatory mediators in the lungs during infection with D39. In contrast to D39, D39Δcps
did not induce TNF-α and IL-6, and triggered low levels of KC in the lung 6 hours after intra-
nasal infection. D39Δcps inoculation, however, induced significant expression of IL-1β and
MIP-2 in a MyD88-dependent manner. The mechanism underlying the induction of cytokine
synthesis by D39Δcps is unclear so far. Production of IL-1β is induced by TLR, and subsequent
activation of intracellular PRRs leads to the formation of the inflammasome required to cleave
the immature pro-form into the mature secreted form of this cytokine [34]. Activation of cyto-
solic PRRs occurs after invasion or after escape of microbes or microbial products from phago-
somes, although the exact processes leading to the activation of intracellular PRRs are still not
completely disentangled [34]. Unencapsulated pneumococci, unlike capsulated pneumococci,
are readily phagocytosed by macrophages [35,36], and phagocytosis of unencapsulated sero-
type 4 pneumococci by dendritic cells was recently found to result in a significant secretion of
IL-1β [37]. Despite low levels of TNF-α, IL-6 and KC in the lung early after infection, D39Δcps
induced profound lung inflammation like D39, as determined by semi-quantitative pathology
scores of lung tissue slides and by measuring neutrophil influx. These data suggest that IL-1β
and MIP-2 are among the driving mediators of the inflammatory response evoked by this
pneumococcal strain.
The serotype of the infecting S. pneumoniae is an important risk factor for the occurrence
of invasive disease and mortality [38]. As such, it is imperative to examine host defense
Fig 5. Reduced chemokine production in the lung of Myd88-/- mice during infection with D39 or D39Δcps. KC/CXCL1 (A and B) and MIP2/CCL2 (C
and D) of wild type (WT, black bars) and Myd88-/- mice (MyD88 KO, white bars) at the indicated time points after inoculation with D39 (A/C) or at 6 or 24 hours
post inoculation D39Δcps (B/D). Data are mean ± SEM (N = 6–8 mice per group at each time point). ***P<0.0005 vs WTmice.
doi:10.1371/journal.pone.0118181.g005
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mechanisms during infection with different pneumococcal serotypes. Previously, we and others
have shown that recognition of S. pneumoniae by TLR2, TLR4 and TLR9 contributes to the
pulmonary host defense response against serotype 2, serotype 3 and serotype 4 pneumococci
[8,12,16,17]. The findings of the present study with a serotype 2 pneumococcal strain and an
unencapsulated mutant of this strain confirm the previously reported critical role of MyD88 in
innate immunity against serotype 4 and 19F pneumococci [18]. Importantly, however, the
more prominent role of MyD88 in host defense against unencapsulated versus encapsulated se-
rotype 2 S. pneumoniae, as documented in the current study, suggests that the pneumococcal
capsule impairs recognition of TLR ligands expressed by this pathogen. This mechanism may
contribute to the well-established role of the capsule in the virulence of S. pneumoniae.
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